Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent
Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial
ETP-ALL May Be Linked To Acute Myeloid Leukemia
CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup
BRCA1 and BRCA2 Mutations Linked To Higher Survival
Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease
Chromosomal Abnormalities Predict Long Median Survival
Analysis Shows No Mortality Benefit From Regular PSA Screening
Ovarian Cancer Symptom Indices May Need to be Re-Evaluated
Self-Collected Pap Smear Tests Could Advance HPV Screening
Trials Approved by NCI CTEP For the Month of January
Palmetto Establishes Coverage For Thyroid Genomic Test
FDA Approves Inlyta Pill For Renal Cell Carcinoma
Trending Stories
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - Imaging’s ride to the bottom in clinical trials—and why it matters now
- She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- NIH says it’s moving away from animal-based models
- The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population
